

References

- Aberg F, Appelkvist EL, Dallner G, Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. *Arch Biochem Biophys* 1992;295(2):230-234.
- Achanzar WE, Ward S. A nematode gene required for sperm vesicle fusion. *J Cell Sci* 1997;110(9):1073-1081.
- Allamand V, Campbell KP. Animal models for muscular dystrophy: Valuable tools for the development of therapies. *Hum Mol Genet* 2000;9(16):2459-2467.
- Among BN, Imamura M, Matsumiya T, Yoshida M, Takeda S. Intracellular localization of dysferlin and its association with the dihydropyridine receptor. *Acta Myol* 2005;24:134-144.
- Anderson LVB, Davison K, Moss JA, Young K, Cullen MJ, Walsh J, *et al.* Dysferlin is a plasma membrane protein and is expressed early in human development. *Hum Mol Genet* 1999;8(6):855-861.
- Anderson LVB, Harrison RM, Pogue R, Vafiadaki E, Pollitt C, Davison K, *et al.* Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). *Neuromuscul Disord* 2000;10(8):553-559.
- Ando Y, Imamura S, Hong YM, Owada MK, Kakunaga T, Kannagi R. Enhancement of calcium sensitivity of lipocortin I in phospholipid binding induced by limited proteolysis and phosphorylation at the amino terminus as analyzed by phospholipid affinity column chromatography. *J Biol Chem* 1989;264(12):6948-6955.
- Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers SM, *et al.* Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. *Nerurology* 2001;57:271-278.
- Aragno M, Tamagno E, Gatto V, Brignardello E, Parola S, Danni O, *et al.* Dehydroepiandrosterone protects tissues of streptozotocin-treated rats against oxidative stress. *Free Radic Biol Med* 1999;26(11-12):1767-1747.
- Aragno M, Mastrocola R, Brignardello E, Catalano M, Robino G, Manti R, *et al.* Dehydroepiandrosterone modulates nuclear factor- κ B activation in hippocampus of diabetic rats. *Endocrinology* 2002;143(9):3250-3258.
- Aragno M, Mastrocola R, Catalano MG, Brignardello E, Danni O, Boccuzzi G. Oxidative stress impairs skeletal muscle repair in diabetic rats. *Diabetes* 2004;53(4):1082-1088.
- Argov Z, Sadeh M, Mazor K, Soffer D, Kahana E, Eisenberg I, *et al.* Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. *Brain* 2000;123(6):1229-1237.
- Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, *et al.* Inflammatory monocytes recruited after skeletal muscle injury switch into anti-inflammatory macrophages to support myogenesis. *J Exp Med* 2007;204(5):1057-1069.

- Babiychuk EB, Draeger A. Annexins in cell membrane dynamics: Ca²⁺-regulated association of lipid microdomains. *J Cell Biol* 2000;150(5):1113-1124.
- Bai J, Wang P, Chapman ER. C₂A activates a cryptic Ca²⁺-triggered membrane penetration activity within the C₂B-domain of synaptotagmin I. *Proc Natl Acad Sci USA* 2002;99(3):1665-1670.
- Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, *et al.* Defective membrane repair in dysferlin-deficient muscular dystrophy. *Nature* 2003;423:168-172.
- Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. *Trends Cell Biol.* 2004;14(4):206-213.
- Barnes JA, Gomes AV. Proteolytic signals in the primary structure of annexins. *Mol Cell Biochem* 2002;231(1-2):1-7.
- Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, *et al.* A gene related to *Caenorhabditis elegans* spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. *Nat Genet* 1998;20:37-42.
- Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, *et al.* Dehydroepiandrosterone (DHEA), DHEA sulphate, and aging: Contribution of DHEAge study to a sociobiomedical issue. *Proc Natl Acad Sci USA* 2000;97:4279-4284.
- Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The *in vivo* evidence. *Nat Rev Drug Discov* 2006;5:493-506.
- Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. *J Bioenerg Biomembr* 2004;36(4):381-386.
- Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. *Am J Physiol* 1996;271(5):C1424-C1437.
- Beckman KB, Ames BN. The free radical theory of aging matures. *Physiol Rev* 1998; 78:547-581.
- Bejaoui K, Hirabayashi K, Hentati F, Haines JL, Ben Hamida C, Belal S, *et al.* Linkage of Miyoshi myopathy (distal autosomal recessive muscular dystrophy) locus to chromosome 2p12-14. *Neurology* 1995;45:768-772.
- Ben Hamida M, Fardeau M, Attia N. Severe childhood muscular dystrophy affecting both sexes and frequent in Tunisia. *Muscle Nerve* 1983;6(7):469-480.
- Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. *Mitochondrion* 2007;7(Suppl 1):S41-S50.
- Bermúdez-Crespo J, López JL. A better understanding of molecular mechanisms underlying human disease. *Proteomics* 2007;1(9):983-1003.



- Bernard CCA, Carnegie PR. Experimental autoimmune encephalomyelitis in mice: Immunologic response to mouse spinal cord and myelin basic proteins. *J Immunol* 1975;114:1537-1540.
- Bethlem J, van Wijngaarden GK. The incidence of ringed fibers and sarcoplasmic masses in normal and diseased muscle. *J Neurol Neurosurg Psychiatr* 1963;26(4):326-332.
- Bhargavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. *Free Radic Res* 2006;40(5):445-453.
- Biggar WD, Gingras M, Fehling DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. *J Pediatr* 2001;138:45-50.
- Birell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through and NF- κ B-independent mechanism. *FASEB J* 2005;19:840-841.
- Bittner RE, Anderson LVB, Burkhardt E, Bashir R, Vafiadaki E, Ivanova S, *et al.* Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. *Nat Genet* 1999;23(2):141-142.
- Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. *Proc Natl Acad Sci USA* 1983;80:4856-4860.
- Bliznakov EG, Hunt GL. The miracle nutrient coenzyme Q. *New York: Bantam Books, 1987*
- Bliznakov EG. Cardiovascular diseases, oxidative stress and antioxidants: The decisive role of coenzyme Q10. *Cardiovasc Res* 1999;43(1):248-249.
- Bockhold KJ, Rosenblatt JD, Partridge TA. Aging normal and dystrophic mouse muscle: Analysis of myogenicity in cultures of living single fibers. *Muscle Nerve* 1998;21(2):173-183.
- Borgonovo B, Cocucci E, Racchetti G, Podini P, Bachi A, Meldolesi J. Regulated exocytosis: A novel, widely expressed system. *Nat Cell Biol* 2002;4:955-962.
- Bork P, Sudol M. The WW domain: A signalling site in dystrophin? *Trends Biochem Sci* 1994;19(12):531-533.
- Borsato C, Padoan R, Stramare R, Fanin M, Angelini C. Limb-girdle muscular dystrophies type 2A and 2B: Clinical and radiological aspects. *Basic Appl Myol* 2006;16(1):17-25.
- Bradamante S, Barengi L, Villa A. Cardiovascular protective effects of resveratrol. *Cardiovasc Drug Rev* 2004;22(3):169-188.
- Brea-Calvo G, Roderíguez-Hernández Á, Fernández-Ayala DJM, Navas P, Sánchez-Alcázar JA. Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines. *Free Radic Biol Med* 2006;40(8):1293-1302.
- Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP. Histological parameters for the quantitative assessment of muscular dystrophy in the *mdx*-mouse. *Neuromuscul Disord* 2004;14(10):675-682.

- Britton S, Freeman T, Vafiadaki E, Keers S, Harrison R, Bushby K, *et al.* The third human FER-1-like protein is highly similar to dysferlin. *Genomics* 2000;68(3):313-321.
- Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, *et al.* Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy. *Neurology* 1989;39:475-481.
- Brummer D, Walter MC, Palmbach M, Knirsch U, Karitzky J, Tomczak R, *et al.* Long-term MRI and clinical follow-up of symptomatic and presymptomatic carriers of dysferlin gene mutation. *Acta Myol* 2005;24(1):6-16.
- Brunn A, Schröder R, Deckert M. The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: An important role for the membrane attack complex. *Acta Neuropathol* 2006;112(3):325-332.
- Bruss M, Homann J, Molderings GJ. Dysferlinopathy as an extra-hepatic cause for the elevation of serum transaminases. *Med Klin (Munich)* 2004;99(6):326-329.
- Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. *EMBO J* 1996;15(8):1753-1765.
- Buetler TM, Renard M, Offord EA, Schneider H, Rüegg UT. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. *Am J Clin Nutr* 2002;75(4):749-753.
- Bushby K. Making sense of the limb-girdle muscular dystrophies. *Brain* 1999(a);122:1403-1420.
- Bushby K. The limb-girdle muscular dystrophies – multiple genes, multiple mechanisms. *Hum Mol Genet* 1999(b);8(10):1875-1882.
- Bushby K. Genetics and the muscular dystrophies. *Dev Med Child Neurol* 2000(a);42(11):780-784.
- Bushby K. Dysferlin and muscular dystrophy. *Acta Neurol Belg* 2000(b);100:142-145.
- Bushby K, Straub V. Nonmolecular treatment for muscular dystrophies. *Curr Opin Neurol* 2005;18(5):511-518.
- Cagliani R, Magri F, Toscano A, Merlini L, Fortunato F, Lamperti C, *et al.* Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. *Hum Mutat* 2005;26(3):283
- Campanaro S, Romualdi C, Fanin M, Celegato B, Pacchioni B, Trevisan S, *et al.* Gene expression profiling in dysferlinopathies using a dedicated muscle array. *Hum Mol Genet* 2002;11:3283-3298.
- Carpenter S, Karpati G. Pathology of skeletal muscle. *New York: Churchill Livingstone, 1984.*
- Carpenter S. Muscle pathology on semithin resin sections. In: Karpati G, Hilton-Jones D, Griggs RC, editors. Disorders of voluntary muscle, 7th Ed. *Cambridge: University Press, 2001.*



- Carpenter S. Electron microscopy in the study of normal and diseased muscle. In: Karpati G, Hilton-Jones D, Griggs RC, editors. *Disorders of voluntary muscle*, 7th Ed. Cambridge: University Press, 2001.
- Cenacchi G, Fanin M, De Giorgi LB, Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. *J Clin Pathol* 2005;58:190-195.
- Cenacchi G, Tarantino L, Corbu A, De Giorgi LB, Fanin M, Pegoraro E, *et al.* The contemporary role of electron microscopy in neuromuscular pathology. *Basic Appl Myol* 2007;17(3-4):167-171.
- Chapman ER, Jahn R. Calcium-dependent interaction of the cytoplasmic region of synaptotagmin with membranes: Autonomous function of a single C2-homologous domain. *J Biol Chem* 1994;269(8):5735-5741.
- Chapman ER, Hanson PI, An S, Jahn R. Ca²⁺ regulates the interaction between synaptotagmin and syntaxin I. *J Biol Chem* 1995;270(40):23667-23671.
- Chazot G, Fournis Y, Robert JM, Aimard G, Devic M. Serum creatine phosphokinase changes during lithium therapy on patients with muscular dystrophy Duchenne type. *Lyon Med* 1972; 228:421-425.
- Chiu YH, Hornsey MA, Klinge L, Jorgensen LH, Laval SH, Charlton R, *et al.* Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. *Hum Mol Genet* 2009;18(11):1976-1989.
- Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. *Biochem Biophys Res Commun* 2008;367(1):290-294.
- Chrobáková T, Hermanová M, Kroupová I, Vondráček P, Maříková T, Mazanec R, *et al.* Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome. *Neuromuscul Disord* 2004;14(10):659-665.
- Cohen L, Morgan J, Schulman S. Diethylstilbestrol: Observations on its use in Duchenne's muscular dystrophy. *Proc Soc Exp Biol Med* 1972;140(3):830-835.
- Cohen L, Morgan J. Diethylstilbestrol effects on serum enzymes and isozymes in muscular dystrophy. *Arch Neurol* 1976;33(7):480-484.
- Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. *Muscle Nerve* 2000;23:1456-1471.
- Comerlato EA; Scola RH, Werneck LC. Limb-girdle muscular dystrophy. An immunohistochemical diagnostic approach. *Arq Neuropsiquiatr* 2005;63(2-A):235-245.
- Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, Butler-Browne GS. *In vivo* satellite cell activation via Myf 5 and MyoD in regenerating mouse skeletal muscle. *J Cell Sci* 1999;112(17):2895-2901.
- Copenhaver WM, Kelly DE, Wood RL. *Bailey's textbook of histology*, 17th Ed. Baltimore: Williams and Wilkins, 1978.
- Crane FL. Biochemical functions of coenzyme Q10. *J Am Coll Nutr* 2001;20(6):591-598.

- Crane FL. Discovery of ubiquinone (coenzyme Q) and an overview of function. *Mitochondrion* 2007;7(Suppl 1):S2-S7.
- Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. *Toxicol Sci* 2004;82(2):614-619.
- Cumming G, Fidler F, Vaux DL. Error bars in experimental biology. *J Cell Biol* 2007;177(1):7-11.
- Dalkilic I, Kunkel LM. Muscular dystrophies: Genes to pathogenesis. *Curr Opin Genet Dev* 2003;13(3):231-238.
- Dallner G, Sindelar PJ. Regulation of ubiquinone metabolism. *Free Radic Biol Med* 2000;29(3-4):285-294.
- Danièle N, Richard I, Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. *Int J Biochem Cell Biol* 2007;39(9):1608-1624.
- Davis DB, Deltmonte AJ, Ly CT, McNally EM. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. *Hum Mol Genet* 2000;9(2):217-226.
- Davis DB, Doherty KR, Delmonte AJ, McNally EM. Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. *J Biol Chem* 2002;277(25):22883-22888.
- Davletov BA, Sudhof TC. A single C2 domain from synaptotagmin I is sufficient for high affinity Ca^{2+} /phospholipid binding. *J Biol Chem* 1993;268(35):26386-26390.
- De Gruchy GC. Clinical Hematology in medical practice. *Acad Med* 1965; 40(3):318
- De Luna N, Gallardo E, Illa I. *In vivo* and *in vitro* dysferlin expression in human muscle satellite cells. *J Neuropathol Exp Neurol* 2004;63(10):1104-1113.
- De Luna N, Gallardo E, Soriano M, Dominique-Perles R, de la Torre C, Rojas-García R, et al. Absence of dysferlin alters myogenin expression and delays human muscle differentiation 'in vivo'. *J Biol Chem* 2006;281(25):17092-17098.
- De Palma S, Morandi L, Mariani E, Begum S, Cerretelli P, Wait R, et al. Proteomic investigation of the molecular pathophysiology of dysferlinopathy. *Proteomics* 2006;6(1):379-385.
- Denk W, Horstmann H. Serial block-face scanning electron microscopy to reconstruct three-dimensional tissue nanostructure. *PLoS Biology* 2004;2(11):e329.
- Diers A, Carl M, Stoltenburg-Didinger G, Vorgerd M, Spuler S. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD 2B) with a novel compound heterozygous mutation in DYSF. *Neuromuscul Disord* 2007;17(2):157-162.
- Disatnik MH, Dhawan J, Yu Y, Beal MF, Whirl MM, Franco AA, et al. Evidence of oxidative stress in *mdx* mouse muscle: Studies of the pre-necrotic state. *J Neurol Sci* 1998;161(1):77-84.



- Doherty KR, McNally EM. Repairing the tears: Dysferlin in muscle membrane repair. *Trends Mol Med* 2003;9(8):327-330.
- Doherty KR, Cave A, Davis DB, Delmonte AJ, Posey A, Earley JU, *et al.* Normal myoblast fusion requires myoferlin. *Development* 2005;132(24):5565-5575.
- Doran P, Gannon J, O'Connell K, Ohlendieck K. Proteomic profiling of animal models mimicking skeletal muscle disorders. *Proteomics* 2007;1(9):1169-1184.
- Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. *Methods Enzymol* 1990;186:421-431.
- Duchenne GB. *L'Electrification localisee at de son application a la pathologie at a la therapeutique.* Paris, France: Bailliere et Fils, 1861.
- Duguez S, Bartoli M, Richard I. Calpain 3: A key regulator of the sarcomere? *FEBS J* 2006;273(15):3427-3436.
- Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. *Curr Opin Genet Dev* 2002;12(3):349-361.
- Ehmsen J, Poon E, Davies K. The dystrophin-associated protein complex. *J Cell Sci* 2002;115:2801-2803.
- Engel AG, Franzini Armstrong C. *Myology: Basic and Applied*, 2nd Ed. New York: McGrawhill, 1994.
- Engel AG, Franzini-Armstrong C. *Myology.* New York: McGraw-Hill, 2004.
- Engelman JA, Zhang X, Galbiati F, Volonté D, Sotgia F, Pestell R, *et al.* Molecular genetics of the caveolin gene family: Implications for human cancers, diabetes, Alzheimer's disease, and muscular dystrophy. *Am J Hum Genet* 1998;63(6):1578-1587.
- Eriksson UJ, Simán CM. Pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in offspring. *Diabetes* 1996;45(11):1497-1502.
- Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. *Biochim Biophys Acta* 1995;1271(1):195-204.
- Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: Malondialdehyde and 4-hydroxynonenal. *Methods Enzymol* 1990;186:407-421
- Eymard B, Romero NB, Leturcq F, Piccolo F, Carrie A, Jeanpierre M, *et al.* Primary adhalinopathy (alpha-sarcoglycanopathy): Clinical, pathological and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. *Neurology* 1997;48:1227-1234.
- Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. *Neuropathol Appl Neurobiol* 2002;28(6):461-470.

Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon JM. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from *Vitis vinifera* cell cultures using *in vitro* tests. *Life Sci* 1997;61(21):2103-2110.

Fenichel GM, Brooke MH, Griggs RC, Mendell JR, Miller JP, Moxley III RT, *et al.* Clinical investigation in Duchenne muscular dystrophy: Penicillamine and vitamin E. *Muscle Nerve* 1988;11(11):1164-1168.

Fernandez I, Arac D, Ubach J, Gerber SH, Shin O, Gao Y, *et al.* Three-dimensional structure of the synaptotagmin I C₂B-domain: Synaptotagmin I as a phospholipid binding machine. *Neuron* 2001;32:1057-1069.

Fernandez-Chacon R, Konigstrofer A, Gerber SH, Garcia J, Matos MF, Stevens CF, *et al.* Synaptotagmin I functions as a calcium regulator of release probability. *Nature* 2001;410:41-49.

Fisher D, Schroers A, Blümcke I, Urbach H, Zerres K, Mortier W, *et al.* Consequences of a novel caveolin-3 mutation in a large German family. *Ann Neurol* 2003;53(2):233-241.

Flucher BE, Terasaki M, Chin HM, Beeler TJ, Daniels MP. Biogenesis of transverse tubules in skeletal muscle *in vitro*. *Dev Biol* 1991;145(1):77-90.

Flucher BE, Takekura H, Franzini-Armstrong C. Development of the excitation-contraction coupling apparatus in skeletal muscle: Association of sarcoplasmic reticulum and transverse tubules with myofibrils. *Dev Biol* 1993;160(1):135-147.

Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. *Proc Natl Acad Sci* 1985;82(13):4513-4516.

Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. *Biochim Biophys Acta* 1995;1271(1):281-286.

Folkers K. Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer therapy. *Biochem Biophys Res Commun* 1996;224(2):358-361.

Foltz CJ, Ullman-Cullere M. Guidelines for assessing the health and condition of mice. *Lab Anim* 1999;28(4):28-32.

Fox JG. The mouse in biomedical research, 2nd Ed. *Bartholds SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL, editors. Burlington, USA: Academic Press, Elsevier Inc., 2007.*

Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. *Lancet* 1993(a);341(8843):454-457.

Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. *Lancet* 1993(b);341(8852):1103-1104.



- Freeman BA, Crapo JD. Biology of disease. Free radicals and tissue injury. *Lab Invest* 1982;47(5):412-426.
- Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, *et al.* Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: Ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). *Hum Mol Genet* 2007;16(6):618-629.
- Gabay C. Cytokine inhibitors in the treatment of rheumatoid arthritis. *Expert Opin Biol Ther* 2002;2(2):135-149.
- Gad SC. Animal models in toxicology. USA, Cary, North Carolina, Gad Consulting Services, 2006.
- Galbiati F, Volonté D, Minetti C, Chu JB, Lisanti MP. Phenotypic behaviour of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD 1C). Retention of LGMD 1C caveolin-3 mutants within the Golgi complex. *J Biol Chem* 1999;274(36):25632-25641.
- Galbiati F, Engelman JA, D, Volonté D, Zhang XL, Minetti C, Li M, *et al.* Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. *J Biol Chem* 2001(a);276(24):21425-21433.
- Galbiati F, Razani B, Lisanti MP. Caveolae and caveolin-3 in muscular dystrophy. *Trends Mol Med* 2001(b);7(10):435-441.
- Gallardo E, Rojas-García R, de Luna N, Pou A, Brown RH Jr, Illa I. Inflammation in dysferlin myopathy: Immunohistochemical characterization of 13 patients. *Neurology* 2001;57:2136-2138.
- Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. *Proc Natl Acad Sci* 1997;94(25):14138-14143.
- Gempel K, Topaloglu H, Talim B, Schneiderat P, Schoser BGH, Hans VH, *et al.* The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETF DH) gene. *Brain* 2007;130(8):2037-2044.
- Gentil BJ, Delphin C, Mbele GO, Deloulme JC, Ferro M, Garin J, *et al.* The giant protein AHNAK is a specific target for the calcium- and zinc-binding S100B protein: Potential implications for Ca²⁺ homeostasis regulation by S100B. *J Biol Chem* 2001;276(26):23253-23261.
- Gentil BJ, Delphin C, Benaud C, Baudier J. Expression of the giant protein AHNAK (desmoyokin) in muscle and lining epithelial cells. *J Histochem Cytochem* 2003;51(3):339-348.
- Gerke V, Moss SE. Annexins: From structure to function. *Physiol Rev* 2002;82(2):331-371.
- Glenny JR Jr. Tyrosine phosphorylation of a 22 kDa protein is correlated with transformation by Rous sarcoma virus. *J Biol Chem* 1989;264(34):20163-20166.

- Glenny JR, Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in RSV-transformed fibroblasts. *Proc Natl Acad Sci USA* 1992;89:10517-10521.
- Glover L, Brown RH Jr. Dysferlin in membrane trafficking and patch repair. *Traffic* 2007;8(7):785-794.
- Godell CM, Smyers ME, Eddleman CS, Ballinger ML, Fishman HM, Bittner GD. Calpain activity promotes the sealing of severed giant axons. *Proc Natl Acad Sci USA* 1997;94(9):4751-4756.
- Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. *Physiol Rev* 2003;83(3):731-801.
- Gómez-Díaz C, Barroso MP, Navas P. Plasma membrane coenzyme Q10 and growth control. *Protoplasma* 2000;214(1-2):19-23.
- Gowers WR. A manual of disease of the nervous system. London: Churchill Livingstone 1886;1:391-394. In Pearce JMS. Gower's sign. *J Neurol Neurosurg Psychiatry* 2000;68(2):149.
- Grounds MD, McGeachie JK. A comparison of muscle precursor replication in crush-injured skeletal muscle of Swiss and BALBc mice. *Cell Tissue Res* 1989;255(2):385-391.
- Grounds MD, Torrisi JO. Anti-TNF α (Remicade[®]) therapy protects dystrophic skeletal muscle from necrosis. *FASEB J* 2004;18(6):676-682.
- Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. *Neurobiol Dis* 2008;31(1):1-19.
- Grounds MD. Complexity of extracellular matrix and skeletal muscle regeneration. In: Schiaffino S, Partridge TA, editors. Skeletal muscle repair and regeneration. Dordrecht, The Netherlands: Springer, 2008.
- Guglieri M, Bushby K. How to go about diagnosing and managing the limb-girdle muscular dystrophies. *Neurol India* 2008;56(3):271-280.
- Guyon JR, Kudryashova E, Potts A, Dalkilic I, Brosius MA, Thompson TG, et al. Calpain 3 cleaves filamin C and regulates its ability to inter with gamma- and delta- sarcoglycans. *Muscle Nerve* 2003;28(4):472-483.
- Hahn KA. Chemotherapy dose calculation and administration in exotic animal species. *Semin Avian Exot Pet* 2005;14(3):193-198.
- Hall-Craggs EC. The significance of longitudinal fiber division in skeletal muscle. *J Neurol Sci* 1972;15(1):27-33. In: Carpenter S, Karpati G. Pathology of skeletal muscle. New York: Churchill Livingstone, 1984.
- Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 2nd Ed. Oxford: Clarendon Press; 1989.



- Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: An overview. *Methods Enzymol* 1990;186:1-85.
- Halliwell B. The wanderings of a free radical. *Free Radic Biol Med* 2009;46:531-542.
- Han R, Campbell KP. Dysferlin and muscle membrane repair. *Curr Opin Cell Biol* 2007;19(4):409-416.
- Harma M, Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole. *Swiss Med Wkly* 2003;133:563-566.
- Harris ED. Regulation of antioxidant enzymes. *FASEB J* 1992;6(9):2675-2683.
- Hartman GH, Renaud DL, Sundaram M, Reed AM. Spondyloarthropathy presenting at a young age: Case report and review. *Skeletal Radiol* 2007;36(2):161-164.
- Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, *et al.* Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. *Nature* 1993;364:501-506.
- Hattersley PG, Ragusa D. Don't forget morphology: The importance of evaluation of blood smears. *Calif Med* 1965;103(3):175-177.
- Hayashi YK. Membrane-repair machinery and muscular dystrophy. *Lancet* 2003;362(9387):843-844.
- Haycock JW, Neil SM, Jones P, Harris JB, Mantle D. Oxidative damage to muscle protein in Duchenne muscular dystrophy. *Neuroreport* 1996;8(1):357-361.
- Hernández-Daviez DJ, Martin A, Laval SH, Lo HP, Cooper ST, North KN, *et al.* Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. *Hum Mol Genet* 2006;15(1):129-142.
- Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I, Brown RH Jr. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. *Ann Neurol* 2002;51(1):129-133.
- Hodges S, Hertz N, Lochwood K, Lister R. CoQ10: Could it have a role in cancer management? *Biofactors* 1999;9(2-4):365-370.
- Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: A trial in subjects with type 2 diabetes. *Eur J Clin Nutr* 2002;56(11):1137-1142.
- Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. *Cell* 1987;51(6):919-928.
- Hohaus A, Person V, Behlke J, Schaper J, Morano I, Haase H. The carboxyl-terminal region of ahnak provides a link between cardiac L-type Ca²⁺ channels and the actin-based cytoskeleton. *FASEB J* 2002;16(10):1205-1216.
- Hohlfeld R, Müller W, Toyka KV. Necrotizing myopathy in SJL mice. *Muscle Nerve* 1988;11(2):184-185.

Horoz M, Bolukbas C, Bolukbas FF, Sabuncu T, Aslan M, Sarifakiogullari S, *et al.* Measurement of the total antioxidant response using a novel automated method in subjects with non-alcoholic steatohepatitis. *BMC Gastroenterol* 2005;5:35-41.

Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, *et al.* Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 2003;425:191-196.

Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21^{WAF1/CIP1}, and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G₂. *Cancer Res* 1999;59(11):2596-2601.

Hu Y, Rahlfs S, Mersh-Sundermann V, Becker K. Resveratrol modulates mRNA transcripts of genes related to redox metabolism and cell proliferation in non-small-cell carcinoma cells. *Biol Chem* 2007;388(2):207-219.

Huang Y, Verheesen P, Roussis A, Frankhuizen W, Ginjaar I, Haldane F, *et al.* Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. *Eur J Hum Genet* 2005;13:721-730.

Huang YC, Laval SH, van Remoortere A, Baudier J, Benaud C, Anderson LVB, *et al.* AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. *FASEB J* 2007;21(3):732-742.

Huang Y, De Morrée A, Van Remoortere A, Bushby K, Frants RR, Den Dunnen JT, *et al.* Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. *Hum Mol Genet* 2008;17(12):1855-1866.

Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. *Proc Soc Exp Biol Med* 1999;222(3):222-235.

Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-García R, Palmer J, *et al.* Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. *Ann Neurol* 2001;49(1):130-134.

Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR, Nylén E, Sukhorukov VS, Poleshchuk VV, *et al.* Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. *Neurology* 2000;55:1931-1933.

Inoue M, Wakayama Y, Kojima H, Shibuya S, Jimi T, Oniki H, *et al.* Expression of myoferlin in skeletal muscles of patients with dysferlinopathy. *Tohoku J Exp Med* 2006;209(2):109-116.

Isfort RJ. Proteomic analysis of striated muscle. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002;771(1-2):155-165.

Ishikawa H. Formation of elaborate networks of T-system tubules in cultured skeletal muscle with special reference to the T-system formation. *J Cell Biol* 1968;38(1):51-66.

Jackson MJ, Jones DA, Edwards RH. Techniques for studying free radical damage in muscular dystrophy. *Med Biol* 1984;62(2):135-138.



- Jacob RA. The integrated antioxidant system. *Nutr Res* 1995;15(5):755-766.
- Jaiswal JK, Andrews NW, Simon SM. Membrane proximal lysosomes are the major vesicle responsible for calcium-dependent exocytosis in nonsecretory cells. *J Cell Biol* 2002;159(4):625-635.
- Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology, the immune system in health and disease. 6th Ed. London: Churchill Livingstone, 2005.
- Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, *et al.* Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science* 1997;275(5297):218-220.
- Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP. Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. *J Biol Chem* 1995;270:27350-27310.
- Kaczor JJ, Hall JE, Payne E, Tarnopolsky MA. Low intensity training decreases markers of oxidative stress in skeletal muscle of mdx mice. *Free Rad Biol Med* 2007;43:145-154.
- Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. *Biochem Biophys Res Commun* 1990;169(3):851-857.
- Kakulas BA. Problems and solutions in the rehabilitation of patients with progressive muscular dystrophy. *Scand J Rehabil Med Suppl* 1999;39:23-37.
- Kar NC, Pearson CM. Catalase, superoxide dismutase, glutathione reductase and thiobarbituric acid-reactive products in normal and dystrophic human muscle. *Clin Chim Acta* 1979;94(3):277-280.
- Kelly DE, Wood RL, Enders AC. Bailey's textbook of microscopic anatomy. 18th Ed. Baltimore, London: Williams and Wilkins, 1984.
- Kesper K, Kornblum C, Reimann J, Lutterbey G, Schröder R, Wattjes MP. Pattern of skeletal muscle involvement in primary dysferlinopathies: A whole-body 3.0-T magnetic resonance imaging study. *Acta Neurol Scand* 2008;120(2):111-118.
- Kettawan A, Takahashi T, Kongkachuichai R, Charoenkiatku S, Kishi T, Okamoto T. Protective effects of coenzyme Q10 on decreased oxidative stress resistance induced by simvastatin. *J Clin Biochem Nutr* 2007;40(3):194-202.
- Kirimlioglu V, Karakayali H, Turkoglu S, Haberal M. Effect of resveratrol on oxidative stress enzymes in rats subjected to 70% partial hepatectomy. *Transplant Proc* 2008;40(1):293-296.
- Klinge L, Laval S, Keers S, Haldane F, Straub V, Barresi R, *et al.* From T-tubule to sarcolemma: Damage-induced dysferlin translocation in early myogenesis. *FASEB J* 2007;21(8):1768-1776.
- Kobayashi K, Izawa T, Kuwamura M, Yamate J. The distribution and characterization of skeletal muscle lesions in dysferlin-deficient SJL and A/J mice. *Exp Toxicol Pathol* 2009; In Press.

Komuro A, Masuda Y, Kobayashi K, Babbitt R, Gunel M, Flavell RA, *et al.* The AHNAKs are a class of giant propeller-like proteins that associate with Ca²⁺ channel proteins of cardiomyocytes and other cells. *Proc Natl Acad Sci USA* 2004;101(12):4053-4058.

Kong KY, Ren J, Kraus M, Finklestein SP, Brown RH Jr. Human umbilical cord blood cells differentiate into muscle in sjl muscular dystrophy mice. *Stem Cells* 2004;22:981-993.

Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? *Eur J Endocrinol* 1998;138:619-620.

Kouno T, Katsumata N, Mukai H, Ando M, Watanabe T. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan. *Jpn J Clin Oncol* 2003;33(6):309-313.

Kudoh J, Wang Y, Minoshima S, Hashimoto T, Amagai M, Nishikawa T, *et al.* Localization of the human AHNAK/desmoyokin gene (AHNAK) to chromosome band 11q12 by somatic cell hybrid analysis and fluorescence in situ hybridization. *Cytogenet Cell Genet* 1995;70(3-4):218-220.

Kunkel LM, Monaco AP, Middlesworth W, Ochs HD, Latt SA. Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. *Proc Natl Acad Sci USA* 1985;82(14):4778-4782.

Lambert O, Gerke V, Bader MF, Porte F, Brisson A. Structural analysis of junctions formed between lipid membranes and several annexins by cryo-electron microscopy. *J Mol Biol* 1997;272(1):42-55.

Langsjoen PH, Langsjoen AM. Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischemia. *Asia Pac Heart J* 1998;7(3):160-168.

Lantos J, Röth E, Czopf L, Nemes J, Gál I. Monitoring of plasma total antioxidant status in different diseases. *Acta Chir Hung* 1997;36(1-4):188-189.

Laval SH, Bushby K. Limb-girdle muscular dystrophies-from genetics to molecular pathology. *Neuropathol Appl Neurobiol* 2004;30:91-105.

Le Ber I, Dubourg O, Benoist JF, Jardel C, Mochel F, Koenig M, *et al.* Muscle coenzyme Q10 deficiencies in ataxia with oculomotor apraxia 1. *Neurology* 2007;68:295-297.

Lee E, Marcucci M, Daniell L, Pypaert M, Weisz OA, Ochoa GC, *et al.* Amphiphysin 2 (Bin 1) and T-tubule biogenesis in muscle. *Science* 2002;297(5584):1193-1196.

Leeson TS, Leeson CR, Paparo AA. Text/Atlas of Histology. *Canada*, Saunders Company, 1988.

Lennon NJ, Kho A, Bacskai BJ, Perlmutter SL, Hyman BT, Brown RH Jr. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. *J Biol Chem* 2003;278(50):50466-50473.

Li ZF, Shelton GD, Engvall E. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. *Am J Pathol* 2005;166(2):491-497.



- Liewluck T, Pongpakdee S, Witoonpanich R, Sangruchi T, Pho-iam T, Limwongse C, *et al.* Novel DYSF mutation in Thai patients with distal myopathy. *Clin Neurol Neurosurg* 2009;111(7):613-618.
- Lindschinger M, Nadlinger K, Adelwöhrer N, Holweg K, Wögerbauer M, Birkmayer J, *et al.* Oxidative stress: Potential of distinct peroxide determination systems. *Clin Chem Lab Med* 2004;42(8):907-914.
- Linnane AW, Kopsidas G, Zhang C, Yarovaya N, Kovalenko S, Papakostopoulos, *et al.* Cellular redox activity of coenzyme Q10: Effect of CoQ10 supplementation on human skeletal muscle. *Free Radic Res* 2002;36(4):445-453.
- Linssen WH, Notermans NC, Van der Graaf Y, Wokke JH, Van Doorn PA, Howeler CJ, *et al.* Miyoshi-type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients. *Brain* 1997;120(11):1989-1996.
- Littarru GP, Jones D, Scholler J, Folkers K. Deficiency of coenzyme Q9 in mice having hereditary muscular dystrophy. *Biochem Biophys Res Commun* 1970;41(5):1306-1313.
- Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: An update. *Curr Opin Clin Nutr Metab Care* 2005;8(6):641-646.
- Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, *et al.* Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. *Nat Genet* 1998;20:31-36.
- Lovering RM, De Deyne PG. Contractile function, sarcolemma integrity, and the loss of dystrophin after skeletal muscle eccentric contraction-induced injury. *Am J Physiol Cell Physiol* 2004;286:C230-C238.
- Lovering RM, Porter NC, Bloch RJ. The muscular dystrophies: From genes to therapies. *Phys Ther* 2005;85(12):1372-1388.
- Mader S. Biology. 7th Ed. *Avenue of the Americas, New York*: McGraw-Hill; 2001.
- Mahjneh I, Marconi G, Bushby K, Anderson LV, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD 2B): A 23-year follow-up study of 10 patients homozygous for the same frameshift dysferlin mutations. *Neuromuscul Disord* 2001;11(1):20-26.
- Marinova EM, Yanishlieva NV, Totseva IR. Anti-oxidant activity and mechanism of action of trans-resveratrol in different lipid systems. *Int J Food Sci Technol* 2002;37:145-152.
- Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. *Mutat Res* 1999;424(1-2):83-95.
- Martensson J, Meister A. Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. *Proc Natl Acad Sci USA* 1989;86(2):471-475.
- Matsuda C, Hayashi YK, Ogawa M, Aoki M, Muaryama K, Nishino I, *et al.* The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. *Hum Mol Genet* 2001;10(17):1761-1766.

- Matsuda C, Kameyama K, Tagawa K, Ogawa M, Suzuki A, Yamaji S, *et al.* Dysferlin interacts with Affixin (β -Parvin) at the sarcolemma. *J Neuropathol Exp Neurol* 2005;64(4):334-340.
- Matsuoka A, Kodama Y, Fukuhara K, Honda S, Hayashi M, Sai K, *et al.* A pilot study of evaluation of the antioxidant activity of resveratrol and its analogue in a 6-month old feeding test in young adult mice. *Food Chem Toxicol* 2008;46(3):1125-1130.
- Maurissen JPJ, Marable BR, Andrus AK, Stebbins KE. Factors affecting grip strength testing. *Neurotoxicol Teratol* 2003;25(5):543-553.
- Mayne R. Muscle. In: Weiss JB, Ayad S, editors. Collagen in health and disease. *New York: Churchill Livingstone*, 1982.
- McDonald CM, Abresch RT, Carter GT, Fowler WM Jr, Johnson ER, Kilmer DD, *et al.* Profiles of neuromuscular diseases: Duchenne muscular dystrophy. *Am J Phys Med Rehabil* 1995;74(5):S70-S92.
- McNally EM, de Sa Moreira E, Duggan DJ, Bonnemann CG, Lisanti MP, Lidov HGW, *et al.* Caveolin-3 in muscular dystrophy. *Hum Mol Genet* 1998;7:871-877.
- McNeil PL. Repairing a torn cell surface: make way, lysosomes to the rescue. *J Cell Sci* 2002;115(5):873-879.
- McNeil AK, Rescher U, Gerke V, McNeil PL. Requirement for annexin A1 in plasma membrane repair. *J Biol Chem* 2006;281(46):35202-35207.
- Mechler F, Imre S, Dioszeghy P. Lipid peroxidation and superoxide dismutase activity in muscle and erythrocytes in Duchenne muscular dystrophy. *J Neurol Sci* 1984;63(3):279-283.
- Mendell JR, Engel WK, Derrer EC. Duchenne muscular dystrophy: Functional ischemia reproduces characteristic lesions. *Science* 1971;172(3988):1143-1145.
- Mercuri E, Pichiecchio A, Allisop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: Past, present and future. *J Magn Reson Imaging* 2007;25(2):433-440.
- Metules T. Duchenne muscular dystrophy. *RN* 2002;65(10):39-44,47.
- Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, *et al.* Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. *Nature* 2002;418:417-422.
- Minetti E, Sotgia F, Bruno C, Scartzzini P, Broda P, Bado M, *et al.* Mutations in the caveolin-3 gene cause autosomal dominant limb girdle muscular dystrophy. *Nat Genet* 1998;18:365-368.
- Mitchell P. The protonmotive Q cycle: A general formulation. *FEBS Lett* 1975;59(2):137-139.
- Mitchell CA, McGeachie JK, Grounds MD. Cellular differences in the regeneration of murine skeletal muscle: A quantitative histological study in SJL/J and Balb/c mice. *Cell Tissue Res* 1992;269(1):159-166.



- Mitchell CA, Grounds MD, Papadimitriou JM. The genotype of bone marrow-derived inflammatory cells does not account for differences in skeletal muscle regeneration between SJL/J and Balb/c mice. *Cell Tissue Res* 1995;280(1):407-413.
- Miyoshi K, Saijo K, Kuryu Y, Tada Y, Otsuka Y, Oshima Y, *et al.* Four cases of distal myopathy in two families. *Jpn J Hum Genet* 1967;12:113.
- Miyoshi K, Kawai H, Iwasa M, Kusaka K, Nishino H. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy: Seventeen cases in eight families including an autopsied case. *Brain* 1986;109(1):31-54.
- Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. *N Engl Med* 2008;358(26):2849-2850.
- Morgan J, Shanahan W, Cohen L. Plasma enzyme determinations in normal and dystrophic mice. *Res Commun Chem Pathol Pharmacol* 1981;31(2):341-356.
- Muller AJ, Baker JF, DuHadaway JB, Ge K, Farmer G, Donover PS, *et al.* Targeted disruption of the murine Bin 1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. *Mol Cell Biol* 2003;23(12):4295-4306.
- Murphy ED. Replica of Hodgkin's Disease in SJL/J Mice. 34th Ann Rept. *Bar Harbor, Maine*: Jackson Lab, 1962-1963:p.26.
- Murphy ME, Kehrer JP. Oxidative stress and muscular dystrophy. *Chem Biol Interact* 1989;69(2-3):101-173.
- Murray JM, Davies KE, Harper PS, Meredith L, Mueller CR, Williamson R. Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy. *Nature* 1982;300:69-71.
- Nagashima T, Chuma T, Mano Y, Goto Y, Hayashi YK, Minami N, *et al.* Dysferlinopathy associated with rigid spine syndrome. *Neuropathology* 2004;24(4):341-346.
- Nalefski EA, Falke JJ. The C₂ domain calcium-binding motif: structure and functional diversity. *Protein Sci* 1996;5(12):2375-2390.
- Nemoto H, Konno S, Nakazora H, Miura H, Kurihara T. Histological and immunological changes of the skeletal muscles in older SJL/J mice. *Eur Neurol* 2007;57(1):19-25.
- Nguyen K, Bassez G, Bernard R, Krahn M, Labelle V, Figarella-Branger D, *et al.* Dysferlin mutations in LGMD 2B, Miyoshi Myopathy, and atypical dysferlinopathies. *Hum Mutat* 2005;26(2):165-176.
- Nguyen F, Guigand L, Goubault-Leroux I, Wyers M, Cherel Y. Microvessel density in muscles of dogs with golden retriever muscular dystrophy. *Neuromuscul Disord* 2005;15(2):154-163.

Nguyen K, Bassez G, Krahn M, Bernard R, Laforet P, Labelle V, *et al.* Phenotypic study in 40 patients with dysferlin gene mutations: High frequency of atypical phenotypes. *Arch Neurol* 2007;64(8):1176-1182.

Niebrój-Dobosz I, Hausmanowa-Petrusewicz. The involvement of oxidative stress in determining the severity and progress of pathological processes in dystrophin-deficient muscles. *Acta Biochim Pol* 2005;52(2):449-452.

Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: Reference interval and effects of life-style factors. *Clin Chem* 1997;43(7):1209-1214.

Norwood FL, Sutherland-Smith AJ, Keep NH, Kendrick-Jones J. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. *Structure* 2000;8:481-491.

Okahashi S, Ogawa G, Suzuki M, Ogata K, Nishino I, Kawai M. Asymptomatic sporadic dysferlinopathy presenting with elevation of serum creatine kinase. Typical distribution of muscle involvement shown by MRI but not by CT. *Intern Med* 2008;47(4):305-307.

Ostdal H, Skibsted LH, Andersen HJ. Formation of long-lived protein radicals in the reaction between H₂O₂-activated metmyoglobin and other proteins. *Free Radic Biol Med* 1997;23(5):754-761.

Ovalle WK, Nahirney PC, Netter FH. Muscle Tissue. Netter's essential histology. Philadelphia: Saunders/Elsevier, 2008

Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. *Clin Chim Acta* 1996;246(1-2):163-182.

Papa S, Schulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. *Mol Cell Biochem* 1997;174(1-2):305-319.

Paradas C, González-Quereda L, De Luna N, Gallardo E, García-Consuegra I, Gómez H, *et al.* A new phenotype of dysferlinopathy with congenital onset. *Neuromuscul Disord* 2009;19(1):21-25.

Parton RG, Way M, Zorzi N, Stang E. Caveolin-3 associates with developing T-tubules during muscle differentiation. *J Cell Biol* 1997;136(1):137-154.

Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, *et al.* Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in *mdx* mice. *Neuromuscul Disord* 2002;12(2):174-182.

Patel TJ, Lieber RL. Force transmission in skeletal muscle: From actomyosin to external tendons. *Exerc Sport Sci Rev* 1997;25:321-363.

Patel P, Harris R, Geddes SM, Strehle E, Watson JD, Bashir R, *et al.* Solution structure of the inner DysF domain of myoferlin and implications for limb girdle muscular dystrophy type 2B. *J Mol Biol* 2008;379(5):981-990.



- Paul AC, Rosenthal N. Different modes of hypertrophy in skeletal muscle fibers. *J Cell Biol* 2002;156(4):751-760.
- Pearce JMS. Gower's sign. *J Neurol Neurosurg Psychiatry* 2000;68(2):149.
- Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. *Proc Natl Acad Sci USA* 1993;90:3710-3714.
- Petrucci TC, Macchia G, Macioce P, Brancaccio A, Paggi P, Ceccarini M. Functional flexibility of dystroglycan, a transmembrane linker between the extracellular matrix and the cytoskeleton. *Cell Mol Biol Lett* 2001;6(2):226.
- Piccolo F, Moore SA, Ford GC, Campbell KP. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. *Ann Neurol* 2000;48(6):902-912.
- Pongpakdee S, Sopassathit V, Phudhichareonrat S, Suthiponpaisan U, Goto K, Hayashi Y, et al. G.P.4.03 Dysferlinopathy in Thai patients and its unusual pathological findings. *Neuromuscul Disord* 2007;12(9-10):788.
- Potgieter M, Pretorius E, Oberholzer HM. Qualitative electron microscopic analysis of cultured chick embryonic cardiac and skeletal muscle cells: The cellular effect of coenzyme Q10 after exposure to Triton X-100. *Ultrastructural Pathology* 2009;33:93-101.
- Pradhan S. Calf-head sign in miyoshi myopathy. *Arch Neurol* 2006;63(10):1414-1417.
- Pradhan S. Diamond on quadriceps: A frequent sign in dysferlinopathy. *Neurology* 2008;70(4):322.
- Pulido SM, Passaquin AC, Leijendekker WJ, Challet C, Wallimann T, Rüegg UT. Creatine supplementation improves intracellular Ca²⁺ handling and survival in *mdx* skeletal muscle cell. *FEBS Lett* 1998;439(3):357-362.
- Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Di Mauro S, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (CoQ2) causes primary Coenzyme Q10 deficiency. *Am J Hum Genet* 2006;78(2):345-349.
- Quinzii CM, Hirano M, DiMauro S. CoQ10 deficiency diseases in adults. *Mitochondrion* 2007;7(Suppl 1):S122-S126.
- Ragusa RJ, Chow CK, Porter JD. Oxidative stress as a potential pathogenic mechanism in animal model of Duchenne muscular dystrophy. *Neuromuscul Disord* 1997;7(6-7):379-380.
- Rando TA. Oxidative stress and the pathogenesis of muscular dystrophies. *Am J Phys Med Rehabil* 2002;81(Suppl 1):S175-S186.
- Raynal P, Pollard HB. Annexins: The problem of assessing the biological role for a gene family of multifunctional Ca²⁺- and phospholipid-binding proteins. *Biochim Biophys Acta* 1994;1197(1):63-93.
- Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. *FASEB J* 2008;22(3):659-661.

- Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. *J Cell Biol* 1963;17:208-211.
- Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. *Methods Enzymol* 1994;234:279-293.
- Rizo J, Sudhof TC. C2-domains, structure and function of a universal Ca²⁺-binding domain. *J Biol Chem* 1998;273(26):15879-15882.
- Robb EL, Page MM, Wiens BE, Stuart JA. Molecular mechanisms of oxidative stress resistance induced by resveratrol: Specific and progressive induction of MnSOD. *Biochem Biophys Res Commun* 2008;367(2):406-412.
- Robertson TA, Maley MAL, Grounds MD, Papadimitriou JM. The role of macrophages in skeletal muscle regeneration with particular reference to chemotaxis. *Exp Cell Res* 1993;207:321-331.
- Roelofs RI, de Arango GS, Law PK, Kinsman D, Buchanan DC, Park JH. Treatment of Duchenne's muscular dystrophy with penicillamine: Results of a double-blind trial. *Arch Neurol* 1979;36(5):266-268.
- Rosenberg NL, Ringel SP, Kotzin BL. Experimental autoimmune myositis in SJL/J mice. *Clin Exp Immunol* 1987;68(1):117-129.
- Ross MH, Kaye GI, Pawlina W. Histology. A text and atlas. 4th Ed. *Baltimore, MD*: Lippincott Williams & Wilkins; 2003.
- Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG, *et al.* Caveolin, a protein component of caveolae membrane coats. *Cell* 1992;68(4):673-682.
- Rötig A, Appelkvist EL, Geromel V, Chretien D, Kadhom N, Edery P, *et al.* Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. *Lancet* 2000;356(9227):391-395.
- Rötig A, Mollet J, Rio M, Munnich A. Infantile and pediatric quinone deficiency diseases. *Mitochondrion* 2007;7(Suppl 1):S112-S121.
- Rouger K, Fornasari B, Armengol V, Jouvion G, Leroux I, Dubreil L, *et al.* Progenitor cell isolation from muscle-derived cells based on adhesion properties. *J Histochem Cytochem* 2007;55(6):607-618.
- Roux I, Safieddine S, Nouvian R, Grati M, Simmler MC, Bahloul A, *et al.* Otoferlin defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. *Cell* 2006;127(2):277-289.
- Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, *et al.* Open label trial of coenzyme Q10 as migraine preventive. *Cephalalgia* 2002;22(2):137-141.
- Ryu H, Ferrante RJ. Emerging chemotherapeutic strategies for Huntington's disease. *Expert Opin Emerg Drugs* 2005;10(2):345-363.



- Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, *et al.* Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: A CoQ10-responsive condition. *Neurology* 2005;65(4):606-608.
- Schiaffino S, Cantini M, Sartore S. T-system formation in cultured rat skeletal tissue. *Tissue Cell* 1977;9(3):437-446.
- Schick F. Whole-body MRI at high field: Technical limits and clinical potential. *Eur Radiol* 2005;15(5):946-959.
- Scholler J, Farley TM, Folkers K. Response of mice with genetic dystrophy to therapy with coenzyme Q. *Int Z Vitaminforsch* 1968;38(3):369-375.
- Schotland DL, Spiro D, Carmel P. Ultrastructural studies of ring fibers in human muscle disease. *J Neuropathol Exp Neurol* 1966;25(3):431-442.
- Selcen D, Stilling G, Engel AG. The earliest pathological alterations in dysferlinopathy. *Neurology* 2001;56:1472-1481.
- Shan X, Chi L, Ke Y, Luo C, Qian S, Gozal D, *et al.* Manganese superoxide dismutase protects mouse cortical neurons from chronic intermittent hypoxia-mediated oxidative damage. *Neurobiol Dis* 2007;28(2):206-215.
- Shao X, Davletov BA, Sutton RB, Sudhof TC, Rizo J. Bipartite Ca²⁺-binding motif in C₂ domains of synaptotagmin and protein kinase C. *Science* 1996;273(5272):248-251.
- Shaul PW, Anderson RGW. Role of plasmalemmal caveolae in signal transduction. *Am J Physiol Lung Cell Mol Physiol* 1998;275(5):L843-L851.
- Shtivelman E, Cohen FE, Bishop JM. A human gene (AHNAK) encoding an unusually large protein with a 1.2-microns polyionic rod structure. *Proc Natl Acad Sci USA* 1992;89(12):5472-5476.
- Shults CW. Coenzyme Q10 in neurodegenerative diseases. *Curr Med Chem* 2003;10(19):1917-1921.
- Sicinski P, Geng Y, Ryder-cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. *Science* 1989;244(4912):1578-1580.
- Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. *Am J Enol Vitic* 1992;43:49-52.
- Sies H. Oxidative stress: oxidants and antioxidants. *Exp Physiol* 1997; 82(2):291-295.
- Silverthorn DU. Human physiology. An integrated approach. 3rd Ed. San Francisco, CA: Pearson, Benjamin Cummings; 2004.
- Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. *Life Sci* 2002;71(6):655-665.

Smythe GM, Shavlakadze T, Roberts P, Davies JK, McGeachie JK, Grounds MD. Age influences the early events of skeletal muscle regeneration: Studies of whole muscle grafts transplanted between young (8 weeks) and old (13-21 months) mice. *Exp Gerontol* 2008;43(6):550-562.

Sohal R, Forster MJ. Coenzyme Q, oxidative stress and aging. *Mitochondrion* 2007;7(Suppl 1):S103-S111.

Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: A molecule whose time has come? And gone? *Clin Biochem* 1997;30(2):91-113.

Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, *et al.* Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. *J Biol Chem* 1996;271(25):15160-15165.

Sorimachi H, Kinbara K, Kimura S, Takahashi M, Ishiura S, Sasagawa N, *et al.* Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. *J Biol Chem* 1995;270(52):31158-31162.

Spuler S, Carl M, Zabojszcza J, Straub V, Bushby K, Moore SA, *et al.* Dysferlin-deficient muscular dystrophy features amyloidosis. *Ann Neurol* 2008;63(3):323-328.

Stadtman ER, Levine RL. Protein oxidation. *Ann N Y Acad Sci* 2000;899:191-208.

Steen MS, Adams ME, Tesch Y, Froehner SC. Amelioration of muscular dystrophy by transgenic expression of Niemann-Pick C1. *Mol Biol Cell* 2009;20(10):146-152.

Stern LZ, Ringel SP, Ziter FA, Menander-Hube KB, Ionasescu V, Pellegrino RJ, *et al.* Drug trial of superoxide dismutase in Duchenne's muscular dystrophy. *Arch Neurol* 1982;39(6):342-346.

Straub V, Rafael JA, Chamberlain JS, Campbell KP. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. *J Cell Biol* 1997;139(2):375-385.

Straub V, Bushby K. Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies. *NeuroRx* 2008;5(4):619-626.

Stübgen JP, Stipp A. Limb girdle muscular dystrophy: A prospective follow-up study of functional impairment. *Muscle Nerve* 1997;20(4):453-460.

Stübgen JP. Limb girdle muscular dystrophy: An interval study of weakness and functional impairment. *J Clin Neuromusc Dis* 2008;9(3):333-340.

Sugita S, Han W, Butz S, Liu X, Fernandez-Chacon R, Lao Y, *et al.* Synaptotagmin VII as a plasma membrane Ca^{2+} sensor in exocytosis. *Neuron* 2001;30(2):459-473.



- Summan M, Warren GL, Mercer RR, Chapman R, Hulderman T, van Rooijen N, *et al.* Macrophages and skeletal muscle regeneration: A clodronate-containing liposome depletion study. *Am J Physiol Regul Integr Comp Physiol* 2006;290(6):R1488-R1495.
- Sun IL, Sun EE, Crane FL, Morrè DJ, Lindgren A, Löw H. Requirement for coenzyme Q in plasma membrane electron transport. *Proc Natl Acad Sci USA* 1992;89(23):11126-11130.
- Sutton RB, Davletov BA, Berhuis AM, Sudhof TC, Sprang SR. Structure of the first C2 domain of synaptotagmin I: A novel Ca²⁺ / phospholipids-binding fold. *Cell* 1995;80(6):929-938.
- Suzuki N, Aoki M, Hinuma Y, Takahashi T, Onodera Y, Ishigaki A, *et al.* Expression profiling with progression of dystrophic change in dysferlin-deficient mice (SJL). *Neurosci Res* 2005;52(1):47-60.
- Tagawa K, Ogawa M, Kawabe K, Yamanaka G, Matsumura T, Goto K, *et al.* Protein and gene analyses of dysferlinopathy in a large group of Japanese muscular dystrophy patients. *J Neurol Sci* 2003;211(1):23-28.
- Takahashi T, Aoki M, Tateyama M, Kondo E, Mizuno T, Onodera Y, *et al.* Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. *Neurology* 2003;60:1799-17804.
- Takaoka MJ. Of the phenolic substances of white hellebore (*Veratrum grandiflorum* Loes. Fil.). *Journal of the Faculty of Science, Hokkaido Imperial University*, 1941;3:1-16.
- Takekura H, Flucher BE, Franzini-Armstrong C. Sequential docking, molecular differentiation, and positioning of T-Tubule/SR junctions in developing mouse skeletal muscle. *Dev Biol* 2001;239(2):204-214.
- Tateyama M, Aoki M, Nishino I, Hayashi YK, Sekiguchi S, Shiga Y, *et al.* Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy. *Neurology* 2002;58:323-325.
- Taveau M, Bourg N, Sillon G, Roundaut C, Bartoli M, Richard I. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. *Mol Cell Biol* 2003;23(24):9127-9135.
- The Jackson Laboratory. *Bar Harbor, Main, USA: JAX Mice Database – 000686 SJL/J, c2007- 2009* [updated 2009; cited 11 November, 2009], www.jax.org/jaxmice
- Theate LG, Crouch RK, Spicer SS. Immunolocalization of CuZn superoxide dismutase in striated muscle. *Histochem J* 1985;17(2):259-262.
- Therrien C, Dodig D, Karpati G, Sinnreich M. Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions. *J Neurol Sci* 2006;250(1):71-78.
- Thomson WHS, Leyburn P, Walton JN. Serum enzyme activity in muscular dystrophy. *Br Med J* 1960;2(5208):1276-1281.
- Tidball JG. Force transmission across muscle cell membranes. *J Biomech* 1991;24(Suppl 1):43-52.

- Tidball JG, Wehling-Henricks M. Damage and inflammation in muscular dystrophy: Potential implications and relationships with autoimmune myositis. *Curr Opin Rheumatol* 2005;17(6):707-713.
- Totsuka T, Watanabe K, Uramoto I, Sakuma K, Mizutani T. Muscular Dystrophy: Centronucleation may reflect a compensatory activation of defective myonuclei. *J Biomed Sci* 1998;5(1):54-61.
- Tran UC, Clarke FC. Endogenous synthesis of coenzyme Q in eukaryotes. *Mitochondrion* 2007;7(Suppl 1):S62-S71.
- Turunen M, Olsen J, Dallner G. Metabolism and function of coenzyme Q. *Biochim Biophys Acta* 2004;1660(1-2):171-199.
- Ueyama H, Kumamoto T, Horinouchi H, Fujimoto S, Aono H, Tsuda T. Clinical heterogeneity in dysferlinopathy. *Intern Med* 2002;41(7):532-536.
- Urtizberea JA, Bassez G, Leturcq F, Nguyen K, Krahn M, Lévy N. Dysferlinopathies. *Neurol India* 2008;56(3):289-297.
- Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A, *et al.* Resveratrol prolongs lifespan and retards the onset of age-related markers in a short lived vertebrate. *Curr Biol* 2006;16(3):296-300.
- Van der Merwe CF, Coetzee J. Quetol651 for general use: a revised formulation. *Comm E M Soc S Afr* 1992;22:31-32.
- Venkat Ratnam D, Ankola DD, Bhardwaj V, Sahana DK, Ravi Kumar MNV. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. *J Control Release* 2006;113(3):189-207.
- Vieira NM, Bueno CR Jr, Brandalise V, Moraes LV, Zucconi E, Secco M, *et al.* SJL dystrophic mice express a significant amount of human muscle proteins following systemic delivery of human adipose-derived stromal cells without immunosuppression. *Stem Cells* 2008;26:2391-2398.
- Von der Hagen M, Laval SH, Cree LM, Haldane F, Pocock M, Wappler I, *et al.* The differential gene expression profiles of proximal and distal groups are altered in pre-pathological dysferlin-deficient mice. *Neuromuscul Disord* 2005;15(12):863-877.
- Wagner KR. Genetic disease of muscle. *Neurol Clin* 2002;20(3):645-678.
- Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. *Brain* 1954;77(2):169-231.
- Walton JN. *Clinical voluntary muscle*. London: Churchill Livingstone; 1981.
- Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, *et al.* Resveratrol protects against global ischemic injury in gerbils. *Brain Res* 2002;958(2):439-447.



- Ward S, Argon Y, Nelson GA. Sperm morphogenesis in wild-type and fertilization-defective mutants of *Caenorhabditis elegans*. *J Cell Biol* 1981;91(1):26-44.
- Washington NL, Ward S. FER-1 regulates Ca²⁺-mediated membrane fusion during *C. elegans* spermatogenesis. *J Cell Sci* 2006;119(12):2552-2562.
- Webster C, Blau HM. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapy. *Somat Cell Mol Genet* 1990;16(6):557-565.
- Weiler T, Greenberg CR, Nylén E, Halliday W, Morgan D, Eggerston D, *et al.* Limb-girdle muscular dystrophy and Miyoshi myopathy in an aboriginal Canadian kindred map to LGMD 2B and segregate with the same haplotype. *Am J Hum Genet* 1996;59(4):872-878.
- Weiler T, Bashir R, Anderson LV, Davison K, Moss JA, Britton S, *et al.* Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). *Hum Mol Genet* 1999;8(5):871-877.
- Weller AH, Magliato SA, Bell KP, Rosenberg NL. Spontaneous myopathy in the SJL/J mouse: Pathology and strength loss. *Muscle Nerve* 1997;20(1):72-82.
- Wenzel K, Zabojszcza J, Carl M, Taubert S, Lass A, Harris CL, *et al.* Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. *J Immunol* 2005;175:6219-6225.
- Yabe I, Kawashima A, Kikuchi S, Higashi T, Fukazawa T, Hamada T, *et al.* Caveolin-3 gene mutation in Japanese with rippling muscle disease. *Acta Neurol Scand* 2003;108(1):47-51.
- Yamaji S, Suzuki A, Sugiyama Y, Koide YI, Yoshida M, Kanamori H, *et al.* A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. *J Cell Biol* 2001;153(6):1251-1264.
- Yamaji S, Suzuki A, Kanamori H, Mishima W, Yoshimi R, Takasaki H, *et al.* Affixin interacts with alpha-actinin and mediates integrin signalling for reorganization of F-actin induced by initial cell-substrate interaction. *J Cell Biol* 2004;165(4):539-551.
- Yasunaga S, Grati M, Cohen-Salmon M, El-Amraoui A, Mustapha M, Salem N, *et al.* A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a non-syndromic form of deafness. *Nat Genet* 1999;21(4):363-369.
- Yasunaga S, Grati M, Chardenoux S, Smith TN, Friedman TB, Lalwani AK, *et al.* OTOF encodes multiple long and short isoforms: Genetic evidence that the long ones underlie recessive deafness DFNB9. *Am J Hum Genet* 2000;67(3):591-600.
- Young B, Lowe JS, Stevens A, Heath JW. Wheater's functional histology. A text and colour atlas. 5th Ed. Elsevier: Churchill Livingstone; 2006.



Yumoto T, Dmochowski L. Light and electron microscope studies of organs and tissues of SJL/J strain mice with reticulum cell neoplasms resembling Hodgkin's disease. *Cancer Res* 1967;27(1):2098-2112.